A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer

Oncology

Volumn 63, Issue 3, 2002, Pages 239-247

  Chen, Li Tzong ^a,b   Liu, Tsang Wu ^a   Wu, Chew Wun ^c   Chung, Tsai Rong ^a   Shiah, Her Shyong ^a   Jan, Chang Ming ^b   Ming Liu, Jacqueline ^a   Whang Peng, Jacqueline ^a   Chang, Jang Yang ^a,c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Cisplatin; Docetaxel; Gastric cancer; High dose 5 fluorouracil; Leucovorin; Phase I

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG MEGADOSE; EDEMA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; LACRIMATION; MALE; MAXIMUM TOLERATED DOSE; MEDICAL ASSESSMENT; MUCOSA INFLAMMATION; NAIL; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMACH ADENOCARCINOMA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; STOMACH NEOPLASMS; TAXOIDS;

EID: 0036969979     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065471     Document Type: Article

References (55)

1. Health and Vital Statistics: Department of Health, the Executive Yuan, ROC, 1994
2. Health and Vital Statistics: Department of Health, the Executive Yuan, ROC, 1994. Comis S: Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat Rep 1974;1:221.
3. Cocconi G, DeLisi V, DiBlasio B: Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treat Rep 1982;66:1263.
4. The Gastrointestinal Tumor Study Group: Phase II/III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 1979;63:1871.
5. Moertel CG, Lavin PT. Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 1979;63:1863.
6. Preusser P, Achterrath W, Wilke H, et al: Chemotherapy of gastric cancer (review). Cancer Treat Rev 1988;15:257.
7. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ, Kang WK, Suh CI, Bang YJ: A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71:3813-3818.
8. Culliunan SA, Moertel CG, Wieand HS, O'Connell M, Poon MA, Krook JE, Mailliard JA, Tschetter LK for the North Central Cancer Treatment Group: Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol 1994;12:412-416.
9. Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V, Brennan: FAMTX vs. etoposide, doxorubicin, and cisplatin: A random assignment trial in gastric cancer. J Clin Oncol 1992;10:541-542.
10. Cocconi G, Bella M, Gilli G, Finardi C: Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: A prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1994;12:2687-2693.
11. Vanhoefer U, Rougier P, Wilke H, et al: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18:2648-2657.
12. Ardalan B, Chua L, Tian E, Reddy R, Sridhar K, Benedetto P, Richman S, Lepaspi A, Waldman S, Morrell L, Feun L, Savaraj N, Livingstone A: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991;9:625-630.
13. Yeh KH, Cheng AL: An alternative method to overcome central venous portable external infusion pump blockage in patients receiving weekly 24-hour high-dose fluorouracil and leucovorin (letter). J Clin Oncol 1994;12:875-876.
14. Hsu CH, Yeh KH, Chen LT, Jacqueline LM, Jan GM, Lin JT, Chen YC, Cheng AL: Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers. Oncology 1997;54:275-280.
15. Yeh KH, Yeh SH, Chang YS, Cheng AL: Minimal toxicity to myeloid progenitor cells of weekly 24-h infusion of high-dose 5-fluorouracil: Direct evidence from colony forming unit-granulocyte and monocyte (CFU-GM) clonogenic assay. Pharmacol Toxicol 2000;86:122-124.
16. Waters JS, Ross PJ, Popescu RA, Cunningham D: New approaches to the treatment of gastrointestinal cancer. Digestion 1997;58:508-519.
17. Chang YF, Li LL, Wu CW, Liu TY, Lui WY, P'eng FK, Chi CW: Paclitaxel-induced apoptosis in human gastric carcinoma cell lines. Cancer 1996;77:14-18.
18. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF: Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 1998;4:269-274.
19. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, Catalano G: Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 1998;9:307-310.
20. Kano Y, Akutsu M, Tsunoda S, Ando J, Matsui J, Suzuki K, Ikeda T, Inoue Y, Adachi KI: Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer 1996;74:704-710.
21. Bokemeyer C, Hartmann JT, Lampe CS, Clemens MR, Quietzsch D, Forkmann L, Kanz L: Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer. Semin Oncol 1997;24(suppl 19):S96-S100.
22. Belani C, Luketich JD, Landreaneau RJ, Kim R, Ramanathan RK, Day R, Ferson PF, Keean RJ, Posner M, Seeger J, Lembersky B: Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus. Semin Oncol 1997;24:89-92.
23. Ilson DH, Ajani JA, Bhalla K, Forastiere AA, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP: Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998;16:1826-1834.
24. Tanaka M, Obata T, Sasaki T: Evaluation of anti-tumor effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo. Eur J Cancer 1996;32A:226-230.
25. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders J, Franklin H, LeBail N, Verweij J: Docetaxel (Taxotere) in advanced gastric cancer: Results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 1994;70:380-383.
26. Taguchi T: An early phase II clinical study of RP56976 (docetaxel) in patients with cancer of the gastrointestinal tract (in Japanese). Gan To Kagaku Ryoho 1994;21:2431-2437.
27. Einzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA, Benson AB 3rd: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996;13:87-93.
28. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger HP, Cavalli F, Alberto P, Castiglione M, Goldhirsch A, on behalf of the Swiss Group for Clinical Cancer Research (SAKK): Taxotere-cisplatin (TC) in advanced gastric carcinoma (AGC): An active drug combination. Proc Am Soc Clin Oncol 1998;17:283.
29. Hainsworth JD, Burris HA III, Erland JB, Thomas M, Greco F: A phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998;16:2164-2168.
30. Greco FA: Docetaxel (Taxotere) administered in weekly schedules. Semin Oncol 1999; 26(suppl 11):S28-S31.
31. Tomiak E, Piccart MJ, Kerger J, Lips S, Awada A, de Valeriola D, Ravoet C, Lossignol D, Sculier JP, Auzannet V: Phase I study of docetaxel administered as a 1-hour infusion on a weekly basis. J Clin Oncol 1994;12:1458-1467.
32. Bissery MC, Vrignaud P, Bayssas M, Lavelle F: Preclinical in vivo activity of docetaxel-containing combination. Proc ASCO 1995;14:1599.
33. National Cancer Institute: Guidelines for the Reporting of Adverse Drug Reaction. Bethesda, Division of Cancer Treatment, National Cancer Institute, 1998.
34. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
35. Chi KH, Chan WK, Shu CH, Law CK, Chen SY, Yen SH, Chen KY: Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma. Cancer 1995;76:2186-2192.
36. Chi KH, Chao Y, Chan WK, Lo SS, Chen SY, Yen SH, Chen KY, Wu CW, Lee SD, Lui WY: Weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin: An effective chemotherapy in advanced gastric cancer. Br J Cancer 1998;77:1984-1988.
37. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alerto P, Castiglione M, Goldhirsch A: Docetaxel (Taxotere)-cisplatin (TC): An effective drug combination in gastric carcinoma. Ann Oncol 2000;11:301-306.
38. Ridwelski K, Gebauer T, Fahlke J, Kroning H, Kettner E, Meyer F, Eichelmann K, Lippert H: Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001;12:47-51.
39. Kettner E, Ridwelski K, Keilholz U, Gallkowski U, Gebauer T, Kroning H, Eichelmann K, Fahlke J, Lippert H: Docetaxel and cisplatin combination chemotherapy for advanced gastric cancer: Results of two phase II studies. Proc ASCO 2001;20:165a.
40. Roth AD, Maibach R, Morant R, Fazio N, Pagani O, de Braud F, Borner MM, Stupp R, Herrmann R, Sessa C, Goldhirsch A, on behalf of the Swiss Group for Clinical Cancer Research (SAKK) and the European Institute of Oncology (EIO): 5FU in protracted continuous i.v. infusion (5-FU piv) can be added to Taxotere-cisplatin (TC) without dose-reduction of TC in advanced gastric carcinoma (AGC). Proc ASCO 1999;18:245a.
41. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP: Docetaxel administration on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-1218.
42. Kouroussis CH, Agelaki S, Mavroudis D, Souglakos J, Kakolyris S, Kalbakis K, Vardakis N, Reppa D, Hatzidaki D, Samonis G, Georgoulias V: A dose escalation study of weekly docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2000;46:488-492.
43. Esmaeli B, Valero V, Ahmadi A, Booser D: Canalicular stenosis secondary to docetaxel (Taxotere): A newly recognized side effect. Ophthalmology 2001;108:994-995.
44. Haidak DJ, Hurwitz BS, Yeung KY: Tear duct fibrosis (dacryostenosis) due to 5-fluorouracil. Ann Intern Med 1978;88:657.
45. Dentino M, Luft RC, Yum NM, Williams DS, Einhorn LH: Long term effect of cis-diammine-dichloride platinum (CDDP) on renal function and structure in man. Cancer 1978;41:1274-1281.
46. Evans TRJ, Harper CL, Beveridge IG, Wastnage R, Mansi JL: A randomized study to determine whether routine intravenous magnesium supplements are necessary in patients receiving cisplatin chemotherapy with continuous infusion 5-fluorouracil. Eur J Cancer 1995;31A:174-178.
47. Specht L, Kornum LS, Sand HH: Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. Ann Oncol 2000;11:845-849.
48. Schoffski P, Catimel G, Planting AST, Droz JP, Verweij J, Schrijvers D, Gras L, Schrijvers A, Wanders J, Hanauske AR, for the European Organization for Research and Treatment of Cancer (EORTC) and Early Clinical Studies Group (ECSG): Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol 1999;10:119-122.
49. Colevas AD, Busse PM, Norris CM, Fried MP, Tishler RB, Poulin M, Fabian RL, Fitzgerald TJ, Dreyfuss A, Peter ES, Read R, Adak S, Costello R, Barton J, Posner MR: Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: A phase I/II trial. J Clin Oncol 1998;16:1331-1339.
50. Posner MR, Glisson B, Frenette G, Al-Sarraf M, Colevas AD, Norris CM, Seroskie JD, Shin DM, Olivares R, Garay CA: Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2001;19:1096-1104.
51. Colevas AD, Norris CM, Tishler RB, Fried MP, Gomolin HI, Amrein P, Nixon A, Lamb C, Costello R, Barton J, Read R, Adak S, Posner MR: Phase II study of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 1999;17:3503-3511.
52. Le Chevalier T, Berille J, Zalcberg JR, Millward MJ, Monnier A, Douillard JY, McKeage MJ, James R, Soulas F, Loret C, Bougon N, Bizzari JP: Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer. Semin Oncol 1999;26(3 suppl 11):13-18.
53. Okamoto H, Watanabe K, Segawa Y, Ichinose Y, Yokoyama A, Yoneda S, Niitani H: Phase II study of docetaxel and cisplatin in patients with previously untreated metastatic non-small-cell lung cancer. Int J Clin Oncol 2000;5:316-322.
54. Schoffski P, Wanders J, Verweij J, Fumoleau P, the EORTC Early Clinical Study Group: Docetaxel and cisplatin in head and neck cancer. Ann Oncol 2000;11:1617-1618.
55. Chun HG, Puccio CA, Mittelman A: Weekly docetaxel and continuous infusion (CI) 5-fluorouracil (5-FU) in elderly patients with cancer of the stomach and distal esophagus. Proc ASCO 2001;20:162a.